- Applied Therapeutics, Inc. entered into a **Controlled Equity OfferingSM Sales Agreement** with **Cantor Fitzgerald & Co.** on **August 29, 2025**.  **[1697532_0000950170-25-112224_aplt-ex10_1.htm:0]** **[1697532_0000950170-25-112224_aplt-20250829.htm:1]** 
- This agreement allows the company to offer and sell up to **$75,000,000** in common stock through "at the market" offerings.  **[1697532_0000950170-25-112224_aplt-20250829.htm:1]** 
- Cantor Fitzgerald & Co. will receive a commission of **3.0%** of the aggregate gross proceeds from any shares sold.  **[1697532_0000950170-25-112224_aplt-20250829.htm:1]** **[1697532_0000950170-25-112224_aplt-ex10_1.htm:47]** 
- Concurrently, the company terminated its previous sales agreement with Leerink Partners LLC, effective **August 29, 2025**.  **[1697532_0000950170-25-112224_aplt-20250829.htm:1]** 
- Under the terminated Leerink Partners Sales Agreement, from **August 11, 2023**, to **August 29, 2025**, Applied Therapeutics, Inc. sold **20,615,976 shares** for net proceeds of approximately **$49.3 million**.  **[1697532_0000950170-25-112224_aplt-20250829.htm:2]**

Applied Therapeutics (APLT)